NovaBay Pharmaceuticals to Participate in Two July Investment Conferences
July 08 2021 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focusing on commercializing Avenova® for the
eye care market and CelleRx® for the beauty market, announces that
management will participate at the upcoming investment
conferences:
- Ladenburg Thalmann Virtual Healthcare Conference being
held July 13-14. Management will present a company overview on July
14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of
the presentation will be available on the NovaBay website.
- A.G.P.’s Virtual MedTech Summer Conference featuring
one-on-one investor meetings on July 29.
“We are addressing extremely large markets with our two
differentiated products, Avenova and CelleRx, and look forward to
sharing details of our growth strategy at these conferences,” said
Justin Hall, CEO of NovaBay Pharmaceuticals. “We have set record
Avenova unit sales for the past three consecutive quarters, while
barely tapping the dry eye market we estimate at 16 million
Americans. We also launched our breakthrough product CelleRx late
last year, bringing a new level of clinical research and innovation
to the beauty category. We are currently rolling out new,
sophisticated media campaigns for both Avenova and CelleRx aimed at
attracting new customers and encouraging repeat usage.”
“We are also actively evaluating opportunities to support
profitable growth through acquisition or licensing of ophthalmic
and skincare products,” he added. “Our experienced commercial
organization, balance sheet and established industry relationships
all give us confidence that we are positioned to pursue new sources
of revenue in order to increase shareholder value.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on high-quality, differentiated, anti-infective consumer
products: Avenova®, the premier antimicrobial lid and lash spray,
CelleRx® Clinical Reset™, a breakthrough product in the beauty
category, and NeutroPhase® Skin and Wound Cleanser for wound
healing. NovaBay’s products are formulated with its patented, pure,
stable, pharmaceutical-grade hypochlorous acid that replicates the
antimicrobial chemicals used by white blood cells to fight
infection. NovaBay’s hypochlorous acid products do not cause
stinging or irritation, are non-toxic and non-sensitizing, making
them completely safe for regular use. Avenova is the only
commercial hypochlorous acid lid and lash spray product clinically
proven to reduce bacterial load on ocular skin surfaces, thus
effectively addressing the underlying cause of bacterial dry
eye.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our current
product offerings, potential future product offerings, and any
future revenue that may result from selling these products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the possibility that the available market
for the Company’s products will not be as large as expected, the
Company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet the
Company’s cash needs, the effect on sales and potential
reputational damage resulting from decisions or actions taken by
regulators, including Warning Letters issued by the FDA, and any
other potential regulatory problems that may arise. Other risks
relating to NovaBay’s business, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on
NovaBay’s progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
CelleRx Clinical Reset Purchasing
Information For NovaBay CelleRx Clinical Reset
purchasing information Please call 877-CELLERX www.CelleRx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210708005029/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024